Results 101 to 110 of about 21,196 (261)
The Impact of Environmental Pollution and Climate Change on Allergic Rhinitis and Lung Diseases
ABSTRACT Environmental pollution and climate change seriously affect human health, leading to the onset and exacerbation of chronic respiratory diseases, such as allergic rhinitis and lung diseases. Over the past several decades, increasing air pollution and environmental exposure owing to global urbanization, industrialization, and rapid economic ...
Xin‐Yan Liu +4 more
wiley +1 more source
Thymic Stromal Lymphopoietin-Mediated Extramedullary Hematopoiesis Promotes Allergic Inflammation [PDF]
Extramedullary hematopoiesis (EMH) refers to the differentiation of hematopoietic stem cells (HSCs) into effector cells that occurs in compartments outside of the bone marrow. Previous studies linked pattern-recognition receptor (PRR)-expressing HSCs, EMH, and immune responses to microbial stimuli.
Siracusa, Mark C. +15 more
openaire +2 more sources
Type 2 Innate Lymphoid Cells in Allergic Disease. [PDF]
Type II innate lymphoid cells (ILC2) are a novel population of lineage-negative cells that produce high levels of Th2 cytokines IL-5 and IL-13. ILC2 are found in human respiratory and gastrointestinal tissue as well as in skin.
Doherty, Taylor A +2 more
core +2 more sources
Cellular Mechanism and Key Insights in Allergen Immunotherapy for Allergic Rhinitis
ABSTRACT Allergic rhinitis (AR) arises from immune responses mediated by immunoglobulin E (IgE) to inhaled allergens, representing one of the most prevalent chronic conditions worldwide. Although AR may not be a serious ailment, it holds clinical relevance as it underpins numerous complications, serves as a major risk factor for suboptimal asthma ...
Zhe Wang +3 more
wiley +1 more source
Functions of thymic stromal lymphopoietin in immunity and disease [PDF]
Thymic stromal lymphopoietin (TSLP) is an interleukin 7-like cytokine expressed mainly by epithelial cells. Current studies provide compelling evidence that TSLP is capable of activating dendritic cells to promote T helper (Th) 2 immune responses. TSLP has also been shown to directly promote Th2 differentiation of naïve CD4(+) T cell and activate ...
Yanlu, Zhang, Baohua, Zhou
openaire +2 more sources
Tissue signals imprint ILC2 identity with anticipatory function. [PDF]
Group 2 innate lymphoid cells (ILC2s) are distributed systemically and produce type 2 cytokines in response to a variety of stimuli, including the epithelial cytokines interleukin (IL)-25, IL-33, and thymic stromal lymphopoietin (TSLP).
Eckalbar, Walter L +10 more
core
ABSTRACT The stratum corneum, as the outermost layer of the skin, functions as a critical barrier that maintains cutaneous hydration and systemic homeostasis. Among its structural lipids, ceramides constitute the most abundant and diverse component. These molecules are essential for the formation of lamellar structures that secure barrier integrity ...
Takashi Sakai
wiley +1 more source
Thymic stromal lymphopoietin: master switch for allergic inflammation [PDF]
Thymic stromal lymphopoietin (TSLP) is an interleukin (IL) 7–like cytokine that triggers dendritic cell–mediated T helper (Th)2 inflammatory responses. TSLP is highly expressed by keratinocytes in skin lesions of patients with atopic dermatitis and is associated with dendritic cell activation in situ, suggesting that TSLP might be a master switch for ...
openaire +2 more sources
Thymic stromal lymphopoietin and the pathophysiology of atopic disease [PDF]
Thymic stromal lymphopoietin (TSLP) is an IL-7-related cytokine expressed predominantly by barrier epithelial cells. TSLP is a potent activator of several cell types, including myeloid-derived dendritic cells, monocytes/macrophages and mast cells. Recent studies have revealed an important role for TSLP in the initiation and progression of allergic ...
Michael M, Miazgowicz +3 more
openaire +2 more sources
ABSTRACT Tralokinumab, an anti‐IL‐13 antibody, is effective for atopic dermatitis (AD); however, its long‐term (> 1 year) effectiveness specific to each anatomical site is unknown in real‐world settings. To evaluate 72‐week effectiveness of tralokinumab on different anatomical sites in AD, we studied 208 patients with moderate‐to‐severe AD treated with
Mizuki Shiba +6 more
wiley +1 more source

